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Introduction: The functional significance of pulmonary hypertension (PH) in COPD is unclear.
The purpose of the study was to define the prevalence, severity and associated functional
impact of PH in patients with severe COPD listed for lung transplant.
Methods: A retrospective review of the Organ Procurement and Tissue Network (OPTN) data-
base between 1997 and 2006 for patients with the primary diagnosis of COPD. Baseline demo-
graphics, hemodynamics, pulmonary function tests, six minute walk distance test (6MWD) and
pre-transplant survival data was analyzed.
Results: 4930 patients with COPD had evaluable right heart catheterization data (RHC). PH was
present in 30.4%, with pulmonary venous hypertension (PVH) accounting for an additional 17.2%
of patients. Patientswith pulmonary hypertensionwalked an average of 28m less than thosewith
normal hemodynamics. Normal hemodynamics group: 261  104 m, PH; 238  106 m (p< 0.01),
PVH: 228  104 m (p < 0.05). In a multivariable analysis, the mean pulmonary artery pressure
(bZ 1.33; pZ 0.01) was an independent predictor of a reduced 6MWD, as were forced vitaldistance test; CI, Confidence interval; COPD, Chronic obstructive pulmonary disease; FEV1%, Forced
%, Forced vital capacity; HR, Hazard ratios; mPAP, Mean pulmonary artery pressure; OPTN, Organ
OP, Pulmonary artery occlusion pressure; PH, Pulmonary hypertension; PVH, Pulmonary venous
terization.
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1878 M.J. Cuttica et al.capacity (bZ 1.48; p < 0.001) and patient age (bZ 1.91; p < 0.001). Both PH (HR 1.23 95%CI
[1.01e1.50]) and PVH (HR 1.35 95%CI [1.11e1.65]) were shown to be independent risk factors for
mortality on thewaiting list, even after adjustment for age sex, race, BMI, lung function, severity
of illness and diabetes (PH: HR 1.27; 95%CI [1.04e1.55], PVH: HR 1.40; 95%CI [1.13e1.73]).
Conclusion: PH is common in advancedCOPDand is associatedwith functional impairmentandan
increased mortality risk. Stratification by RHC determined pulmonary hemodynamics appears
important in distinguishing distinct clinical phenotypes.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Pulmonary hypertension (PH) is common in advanced
chronic obstructive lung disease (COPD). The prevalence
has been reported from as low as 1% to as high as 50% in
different series.1,2 This variability has likely been the result
of differences in the definition of PH, inclusion of other
contributory causes and the patient population studied.
The presence of PH in COPD has significant implications for
morbidity and mortality.3 Specifically, the influence of the
pulmonary vascular resistance on survival in COPD patients
is similar to that of the FEV1.
4,5 In 84 patients with COPD
who had right heart catheterizations (RHC) prior to the
initiation of long term oxygen therapy, those with an initial
mean pulmonary artery pressure (mPAP) of 25 mmHg had
a 5 year survival of 62.2% compared to those with PH who
had a 5 year survival of only 36.3% (p < 0.001). From the
same study, a multivariable analysis revealed that baseline
mPAP was the best prognostic factor in COPD patients
receiving long term oxygen therapy and performed better
than the FEV1, the degree of hypoxia, or the presence of
hypercapnia in predicting outcomes.5
It was previously thought that PH in COPD occurred in
the setting of severe airflow obstruction and was most
commonly mild in nature. Recent studies have shown that
there may be a subset of patients that develop more severe
PH in the setting of relatively well-preserved lung function
suggesting the likelihood of a distinct COPD phenotype.2
Despite a growing body of literature on PH in COPD, the
association between pulmonary artery pressure and func-
tional endpoints such as the sixminutewalk distance (6MWD)
has not been well explored. In addition, the role of an
elevated pulmonary artery occlusion pressure (PAOP) as
a cause or contributing factor to PHassociatedwith COPDhas
not previously been described. Using data from the Organ
Procurement and Tissue Network (OPTN) database of COPD
patients listed for lung transplant, we sought to determine
the prevalence of PH as defined by RHC and to further
determine the role an elevated PAOP plays in this diagnosis.
We also sought to determine if there were functional and
survival differences between subgroups of patients with and
without PH. Specifically, we hypothesized that increased
pulmonary artery pressures would be associatedwith a lower
6MWD and greater mortality in patients with COPD.Methods
We performed a retrospective study of the OPTN database
of all COPD patients listed for lung transplant between 1997and 2006. IRB approval and patient consent were not
required for this retrospective review of a publicly avail-
able database. The following parameters were available for
analysis: age, height, weight, ethnicity, mPAP, Forced Vital
Capacity (FVC%), Forced Expiratory Volume in 1 s (FEV1%),
the FEV1/FVC ratio, the PAOP, oxygen requirements, New
York Heart Association (NYHA) class and the 6MWD.
Patients were categorized into one of four groupings: 1.
Normal hemodynamics defined as mPAP <25mmHG, and
PAOP 15 mmHg, 2. Pulmonary hypertension defined as
a mPAP of 25 mmHg with a PAOP 15 mmHg (PH group), 3.
Pulmonary venous hypertension defined as a mPAP
25 mmHg with a PAOP of >15 mmHg (PVH group), and 4.
Normal pulmonary artery pressure with an elevated PAOP
defined as a mPAP <25 mmHG with a PAOP  15 mmHg
(Isolated Elevation of PAOP group). Patients were further
categorized as having mild to moderate PH (mPAP
25e34 mmHg) and severe PH (mPAP35 mmHg)
Statistics
Data is presented as mean  standard deviation or
frequency and percent. Univariable and multivariable
analyses were performed in patients in whom the mPAP,
PAOP, FEV1%, FVC% and 6MWD was available to assess which
factors correlated with the six minute walk distance.
Comparison of means was done via Student’s t tests.
Multiple means were compared using analysis of variance
(ANOVA) with Bonferroni adjustment for multiple compar-
isons. The relationships between given parameters and the
6MWD were assessed by univariable and multivariable
linear regression. Co-variables included in statistical
models were pre-specified based on a known or hypothe-
sized association with functional capacity in COPD and PH.
Although FVC and FEV1 percent predicted were used in the
model age, sex, height and weight were specifically
included as co-variables given their direct impact on six
minute walk distance.6
Cox proportional hazard models were performed to
evaluate survival on the transplant list after adjustment for
age, sex, ethnicity, height, weight, FEV1, FVC, and NYHA
class. Patients were included in the survival analysis if they
remained alive at the end of the study period or if they
were removed from the list for death or transplant.
Transplanted patients were right censored as alive on the
day of transplant, and for all patients the time variable was
calculated from the date of listing. Post-transplantation
survival was not included or calculated. Adjusted hazard
ratios (HR) and 95% confidence intervals (CI) were
generated.
Figure 1 Distribution of the hemodynamic profile in patients
with COPD listed for lung transplant.
Categorization and impact of PH in COPD 1879Statistical analysis was completed using Graphpad soft-
ware (Prizm 4, San Diego, California) and STAT software
(SAS, Cary, North Carolina).
Results
There were 5909 patients with COPD listed for lung trans-
plantation between 1997 and 2006. Data was missing or
erroneous in 979 patients who were therefore not included
in the analysis. The prevalence of the four hemodynamic
groups was determined from the remaining 4930 patients.
There was no significant difference in age, gender distri-
bution, height, distribution of ethnicity, FVC%, FEV1%, and
oxygen requirement between the four hemodynamic cate-
gories. Subjects with an elevated PAOP tended to weigh
more and subjects with normal hemodynamics had a longer
6MWD (Table 1).
The prevalence of PH was 30.4% (1499/4930), of whom
4.0% (196/4930) had severe PH. An additional 17.2% (847/
4930) of patients had PVH and 4.2% (208/4930) had an iso-
lated elevation of PAOP. Remarkably, only 48.2% of patients
had “normal” hemodynamics characterized by a mPAP less
than 25 mmHg with a PAOP less than 15 mmHg (Fig. 1). The
distribution of mPAP in all patients with either normal or
elevated PAOP revealed that the largest proportion of cases
fell into the 21e24mmHg range, which although notmeeting
the traditional definition of PH is elevated above the repor-
ted normal value of 14.8  3.8 mmHg.7 Furthermore, we
found that as the mPAP increases so does the proportion of
patients with PVH (Fig. 2).
The 6MWD was evaluated as a marker of functional
status. There was no significant difference in demo-
graphics, oxygen requirements or hemodynamic variables
between the 1154 patients with and the 3664 patients
without 6MWD recorded in the database (Table 2). The
mean 6MWD for patients in the normal hemodynamics group
was 261  104 m. The distance was not significantly






Age 56  6.2 56  6.1
Female 1325 (55.8) 817 (54.5
Ht (cm) 168  16.1 168  12
Wt (kg) 65  14.8 69  15.5
Ethnicity
White 2262 (95.2) 1373 (91.
Black 80 (3.4) 95 (6.3)
Hispanic 22 (1.0) 17 (1.1)
Other 12 (0.5) 14 (0.9)
FVC % predicted 56  18 52  18
FEV1% predicted 22  9.6 22  10.4
Oxygen requirement 2  1.4 2.3  1.6
6MWD (m) 261  104 238  10
SD or (%).
*p Z 0.012, **p < 0.01.
PAOP; pulmonary artery occlusion pressure, FVC %; forced vital cap
percent predicted, 6MWD; six minute walk distance.(259  100 m, p > 0.05), while it was significantly lower in
both the PH group (238  106 m, p < 0.01) and the PVH
group (228  104 m, p < 0.05) (Table 1). Even after
adjustment for FEV1%, FVC%, height, weight, ethnicity,
gender and age at listing, the 6MWD in the PH group
remained significantly lower with an adjusted 6MWD in the
normal hemodynamic group of 253  26 m versus
247  26 m for the PH group (p Z 0.014).
An evaluation of the association between the mPAP and
6MWD independent of the degree of lung function impair-
ment was performed using multivariable linear regression.
There were 1071 subjects with 6MWD and comparable
pulmonary function tests available for analysis. In uni-
variable analyses both the FEV1% (bZ 1.44; p < 0.001), and
FVC% (bZ 1.51; p < 0.001) were associated with a reduced
6MWD, while the mPAP (b Z 1.74; p < 0.001) and PAOP
(b Z 1.37; p Z 0.03) had an inverse association with the
6MWD. In multivariable analysis the mPAP was found to be
an independent predictor of a low 6MWD (b Z 1.33;







56  6.3 56  6.1
) 427 (50.4) 114 (54.8)
.5 169  16.2 167  10.0
75.3  16.6 70.2  16.2
6) 771 (91.0) 199 (95.7)
58 (7.8) 5 (2.4)
11 (1.3) 3 (1.4)
7 (0.8) 1 (0.5)
52  18 54  18
21  9.2 22  9.9
2.4  1.4 2.1  1.2
6* 228  104** 259  100
acity percent predicted, FEV1%; forced expiratory volume in 1 s
Figure 2 Histogram distribution of the mean pulmonary
artery pressures in all COPD patients listed for lung trans-
plantation, stratified by normal or elevated pulmonary artery
occlusion pressure.
1880 M.J. Cuttica et al.p < 0.001) and age at listing (b Z 1.91; p < 0.001) with
the 6MWD was also preserved (Table 3).
A survival analysis of the four predefined hemody-
namic groups was performed and showed that both the
PH (HR 1.23; 95%CI [1.01e1.50]) and PVH (HR 1.35; 95%CI
[1.11e1.65]) subgroups had an increased risk of death.
The Isolated Elevation of PAOP group did not have an
increased risk of death on the waiting list (HR 0.95; 95%CI
[0.66e1.36] (Fig. 3). After adjustment for age, sex, race,
BMI, lung function, severity of illness and diabetes, the
increased risk of death persisted in both PH groups (PH:
HR 1.27; 95%CI [1.04e1.55], and PVH: HR 1.40; 95%CI
[1.13e1.73]) (Table 4).Table 2 Comparison of patients with and without 6MWD
data.
With 6MWD Missing 6MWD
Number 1154 3664
Age (mean) 58 (5.9) 56 (6.2)
Sex (% female) 54.9% 54.4%
Height (cm) 167.6 (10.1) 168.4 (10.1)






PAOP 12.0 (5.1) 11.9 (5.2)
mPAP 25.2 (6.9) 24.8 (7.0)
FVC 55 (16) 54 (17)
FEV1 22 (10.1) 22 (9.1)
Oxygen requirement 2.6 (1.6) 2.1 (1.2)
6MWD; 6 minute walk distance, PAOP; pulmonary artery
occlusion pressure, mPAP; mean pulmonary artery pressure,
FVC; forced vital capacity, FEV1; forced expiratory volume.Discussion
We report the largest series to date of right heart cathe-
terization confirmed pulmonary hypertension in a pop-
ulation of COPD patients listed for lung transplantation. We
categorized patients into one of four groups based on an
elevated or normal mPAP with or without an elevated PAOP.
Based on this categorization, we evaluated whether there
were differences in the functional status or outcomes in the
four hemodynamic groups. We demonstrated that PH of any
cause resulted in significant functional impairment as
assessed by the 6MWD and was further associated with an
increased risk of mortality. We believe this categorization
underscores the existence of various hemodynamic pheno-
types in COPD which might be important in providing
a framework for future studies of PH associated with COPD.
To our knowledge, this is only the second report of PH as an
independent variable effecting functional status in patients
with COPD.8 It is also is the largest report to date demon-
strating an impact of PH on survival in patients with COPD.
We found the prevalence of PH in our cohort of patients
with advanced COPD to be 30.4%. We also demonstrated
that a significant proportion of patients with advanced
COPD (17.2%) have evidence of PVH, and that as the
severity of pulmonary hypertension increases so does the
proportion of these patients. Although 16.5% of subjects
had missing catheterization data which could introduce
bias into these estimates of prevalence the findings are
consistent with a previously reported prevalence of
unrecognized heart failure of 20.5% in elderly patients with
stable COPD.8 Of these patients, approximately half were
found to have left ventricular systolic dysfunction and half
isolated diastolic dysfunction.9 Although we were unable to
provide an assessment of systolic function, we suspect that
the majority of our patients with elevated PAOPs had dia-
stolic dysfunction, since significant systolic dysfunction
(left ventricular ejection fraction <40%) is commonly
regarded as a contraindication to lung transplantation. This
highlights the fact that both PH and diastolic heart
dysfunction represent independent comorbidities in
patients with COPD.
The 6MWD is a reliable, non-invasive, and validated
measure of functional status.10,11 A low 6MWD is an
important predictor of mortality in both COPD and pulmo-
nary arterial hypertension patient populations.12,13 There is
little data linking elevations in pulmonary artery pressures
with functional ability in COPD patients.8 By using the
6MWD as a surrogate of functional ability, we evaluated the
effects of PH on functional capacity in over 1000 patients
with severe COPD. We found that patients with PH walked
an average of 28 m less than those with normal hemody-
namics. Furthermore, after adjusting for lung function and
patient demographics the PH group walk distance was 6 m
lower. This finding was statistically significant, the clinical
significance of a 6 m difference particularly in a multivari-
able analysis is uncertain. We thereby demonstrated
a negative influence of PH on patients’ functional status.
Specifically, in univariable analysis the FEV1%, FVC%, and
mPAP all appeared to correlate with a lowered six minute
walk distance. However, multivariable analysis demon-
strated that in addition to the FVC% and age, the mean
Table 3 Univariable and Multivariable analysis of six minute walk distance in patients with COPD.
Variable Univariable (b) (R2) p value Multivariablea (b) p value
FEV1 1.44 0.019 <0.001 0.26 0.5
FVC 1.51 0.054 <0.001 1.48 <0.001
mPAP 1.74 0.013 <0.001 L1.33 0.01
PAOP 1.37 0.004 0.03 0.32 0.7
Height (cm) 0.15 0.78
Weight (kg) 0.07 0.8
Ethnicity 7.04 0.25
Gender 13.2 0.16
Age at listing L1.91 <0.001
FEV1; forced expiratory volume, FVC; forced vital capacity, mPAP; mean pulmonary artery pressure, PAOP; pulmonary artery occlusion
pressure.
a R-squared value for multivariable model is 0.078.
Categorization and impact of PH in COPD 1881pulmonary artery pressure was an independent predictor of
a reduced functional status. The b coefficient of 1.33
indicates that every 1 mmHg rise in the mean pulmonary
artery pressure is associated with a 1.33 m decline in the six
minute walk distance.
It is expected that markers of worsening lung function
would correlate with functional decline. It is interesting
that in our cohort the FEV1% was not predictive of a lower
functional status. This may be reflective of the pre-trans-
plant population in which there tends to be a “clustering”
of patients around very low FEV1% values. We expect that
the correlation of the FVC% to the 6MWD resulted from the
wider range and variability of this measurement in our
population. It may also reflect that the FVC% is a surrogate
for hyperinflation in this COPD cohort. Alternatively, it
could also be a marker for deconditioning and weakness.
We attempted to assess the likelihood of survival on the
transplant list based on the hemodynamic profile of the
patients. Although previous studies have shown that
elevated pulmonary artery pressures in patients with COPD
have a negative impact on survival, ours is the largest series
to date to confirm this association.5 By censoring patients
as alive at the time of transplant, we attempted to mini-
mize the bias of changed survival trajectory afterFigure 3 Survival curve based on hemodynamic grouping.transplant and through our analysis demonstrated that
patients with PH and PVH were at greater risk of dying on
the transplant list. This increased mortality persisted even
after controlling for confounders such as age, ethnicity,
BMI, lung function and NYHA class.
There are a number of limitations to our study. First, it is
retrospective and the quality of the data is dependent on
appropriate coding and input from multiple transplant
centers. Since close to 5000 patients had right heart cath-
eterizations, we believe that this would compensate for
any coding or other errors of input. It is unclear why so
many patients did not have six minute walk distance
recorded in the database and this could potentially intro-
duce bias into this aspect of our analysis. Based on the
available data there was no obvious difference between
those undergoing six minute walk test and those that did
not. The OPTN database does not record data that might
have shed further insight into our analysis, such as the
diffusion capacity for carbon monoxide and echocardiog-
raphy. Finally, the cohort as a whole is a highly select
population who qualified for lung transplantation. There-
fore our data might not be applicable to all COPD patients.
However, this is also a strength of the study in that through
the stringent transplant selection process, patients with
significant confounding comorbid conditions that might
affect their functional status and mortality risk were likely
screened out.
In conclusion, we demonstrate in the largest series to
date the adverse impact of pulmonary hypertension in
COPD patients with effects on both survival and functional
status. Our study underscores the need for right heart
catheterization in establishing an accurate diagnosis to
distinguish PH from PVH. Each of these diagnoses has
potential implications for the management of these
patients. Specifically, if studies of targeted PH therapy are
to be considered in this patient population, then right heart
catheterization is needed to fully characterize the pulmo-
nary hypertension and thus enable appropriate candidate
screening. The lack of this precision in subject selection
may be a contributing factor in the negative outcomes seen
in trials such as the Bosentan in severe COPD trial which
relied on echocardiogram alone to define pulmonary
hypertension.14 Future trials are more likely to be
successful if the COPD phenotype with a proportionately
Table 4 Association of Hemodynamics and Time to Death on Transplant List.
Unadjusted Adjusteda
Parameter Hazards ratio 95% CI Hazards Ratio 95% CI
Normal Hemodynamics e e e e
Pulmonary Hypertension 1.23 1.01e1.50 1.27 1.04e1.55
PVH 1.35 1.11e1.65 1.40 1.13e1.73
Isolated elevation of PAOP 0.95 0.66e1.36 1.02 1.01e1.04
PVH; pulmonary venous hypertension, PAOP; pulmonary artery occlusion pressure.
a adjusted for Age, Ethnicity, BMI, FEV1, FVC, sex, NYHA Class, diabetes (yes/no).
1882 M.J. Cuttica et al.greater vascular disease component is targeted. The hope
therefore is that our description of the scope and impact of
this supervening complication will stimulate interest and
provide a foundation for further studies of pulmonary
hypertension in COPD.Acknowledgement
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